Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

Ibrutinib activates CYLD. 2 / 2

| 2

➶

reach

"BTK inhibitor PCI-32765 promoted CYLD dependent apoptosis in rituximab resistant non-GCB-DLBCL cells."

33827598

➶

reach

"Previous researches in CLL indicated that BTK inhibitor ibrutinib could largely increase CYLD activity through increasing CYLD miRNA transcription, which could inhibit cells proliferation in CLL [XREF_BIBR]."

33827598

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...